Dividend Dhamaka! SmallCap Healthcare Stock Jumps 20% After Q4 Result, To Pay BIG Dividend Rs 21; Do You Own?

Dividend Dhamaka: Shares of Thyrocare surged 19.9% to touch Thursday's intraday high amid heightened investors interest around the stock post Q4 results and dividend announcements. The healthcare services sector company announced a 210% dividend compared to its face value.

Thyrocare shares surged nearly 19.9% during the stock market opening session to Rs 921 apiece on BSE on Thursday. The company scrip was trading 13.4% higher at
872.5 apiece with a market capitalisation of Rs 4,623.41 crore on BSE at 11:20 am.

Thyrocare Share Price Movement

The BSE SmallCap stock value has increased significantly over the past few days. The company scrip's value has surged nearly 22.86% in last one week, and over 10.39% in one month. However, it is still trading lower compared to its initial value in the beginning of the year 2025.

Thyrocare Dividend Announcement

The company, on Wednesday, had declared a final dividend of Rs 21 per equity shares. The dividend will be finalised after the approval of shareholders at the ensuing shareholders meeting.

Recommended a final dividend of INR 21 per equity share, subject to the approval of shareholders at the ensuing shareholders' meeting. Thyrocare dividend will be paid within a month after the annual general meeting.

"The Board has recommended a Final Dividend of Rs. 21/- per equity share for the financial year 2024-25 subject to the approval of the shareholders at the ensuing Annual General Meeting ("AGM") of the Company. The Dividend, if declared by shareholders, shall be paid within 30 days from the date of the AGM," read a company stock exchange filing released on Wednesday.

Thyrocare Q4 Result

The healthcare services company reported a whopping 88% annual increase to Rs 32.5 crore, according to its press release. In Addition to this, Thyrocare witnessed a 21% year-on-year rise in its consolidated revenue. The revenue growth was fuelled by the development of pathology and radiology segments which grew by 23% YoY and nearly 7% YoY.

Company's total volume in the financial year 2024-25 increased to 167.9 million, largest by far on volume. Thyrocare Technology's consolidated gross margin stood at 74%, and normalized EBITDA margin was 35%. Whereas, its standalone normalised EBITDA improved by 72% annually. Thyrocare's consolidated cash reserves as of March 2025 stood at Rs 191.8 crore. The company also expanded its operations in certain areas of India, as it opened new labs in Bhagalpur and Kashmir.

Thyrocare is an automated laboratory chain that has a presence in more than 16 Indian states. It has a strong presence in the diagnostic services, laboratory operations. It has a franchise base of more than 11,000 and processes more than 460,000 diagnostic and screening investigations each night, according to the company press release. It obtained accreditations like ISO 9001-2000 rating, which was upgraded to ISO 9001:2015, and National Accreditation Board for Testing and Calibration Laboratories (NABL) and College of American Pathologists (CAP) accreditations.

Apart from declaring Q4 results for FY25 and final dividend, the company also announced that its board of directors have approved the appointment of secretarial auditors, and reappointment of cost auditors.